ReviewHandbook of experimental pharmacology2012
Dopamine receptor signaling and current and future antipsychotic drugs.
Review in Handbook of experimental pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 106 citations in OpenAlex.
- Article
- Investigating the Synergistic Effect of the Cannabis Extract PHEC-66 and Chemotherapeutic Agents on Human Melanoma Cells.International journal of molecular sciences · 2026Article
- Host GPCR-cAMP signaling balances Gαs and Gαi activity to control intracellularbioRxiv : the preprint server for biology · 2026Article
- Insight into molecular and neural mechanisms of general anesthesia from the invertebrate modelZoological research · 2025Review
- Effects of dopamine receptor antagonists and radiation on mouse neural stem/progenitor cells.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024Article
- The effects of different types of social interactions on the electrophysiology of neurons in the nucleus accumbens in rodents.Neuroscience and biobehavioral reviews · 2024Review
- Olanzapine's effects on hypothalamic transcriptomics and kinase activity.Psychoneuroendocrinology · 2024Article
- Regulation of neuronal circHomer1 biogenesis by PKA/CREB/ERK-mediated pathways and effects of glutamate and dopamine receptor blockade.Research square · 2024Article
- The Placebo Effect in Psychosis: Why It Matters and How to Measure It.Biological psychiatry global open science · 2023Review
- Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis.International journal of molecular sciences · 2023Review
- Dopaminergic System in Promoting Recovery from General Anesthesia.Brain sciences · 2023Review
- Therapeutic Potential of Dopamine and Related Drugs as Anti-Inflammatories and Antioxidants in Neuronal and Non-Neuronal Pathologies.Pharmaceutics · 2023Review
- Dopamine, Immunity, and Disease.Pharmacological reviews · 2023Review
- Longitudinal multi-omics alterations response to 8-week risperidone monotherapy: Evidence linking cortical thickness, transcriptomics and epigenetics.Frontiers in psychiatry · 2023Article
- Developing Photoaffinity Probes for Dopamine Receptor DACS chemical neuroscience · 2022Article
- Examining the role of paraoxonase 2 in the dopaminergic system of the mouse brain.BMC neuroscience · 2022Article
- Dopamine receptor signaling regulates fibrotic activation of retinal pigmented epithelial cells.American journal of physiology. Cell physiology · 2022Article
- Discovery and characterization of benzyloxy piperidine based dopamine 4 receptor antagonists.Bioorganic & medicinal chemistry letters · 2022Article
- Allosteric modulation of dopamine DPharmacological reports : PR · 2022Article
- Aripiprazole Offsets Mutant ATXN3-Induced Motor Dysfunction by Targeting Dopamine DBiomedicines · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
All currently efficacious antipsychotic drugs have as part of their mechanism the ability to attenuate some or all of the signaling through the dopamine D(2) receptor. More recently, the dopamine D(1) receptor has been hypothesized to be a promising target for the treatment of negative and/or cognitive aspects of schizophrenia that are not improved by current antipsychotics. Although cAMP has been presumed to be the primary messenger for signaling through the dopamine receptors, the last decade has unveiled a complexity that has provided exciting avenues for the future discovery of antipsychotic drugs (APDs). We review the signaling mechanisms of currently approved APDs at dopamine D(2) receptors, and note that aripiprazole is a compound that is clearly differentiated from other approved drugs. Although aripiprazole has been postulated to cause dopamine stabilization due to its partial D(2) agonist properties, a body of literature suggests that an alternative mechanism, functional selectivity, is of primary importance. Finally, we review the signaling at dopamine D(1) receptors, and the idea that drugs that activate D(1) receptors may have use as APDs for improving negative and cognitive symptoms. We address the current state of drug discovery in the D(1) area and its relationship to novel signaling mechanisms. Our conclusion is that although the first APD targeting dopamine receptors was discovered more than a half-century ago, recent research advances offer the possibility that novel and/or improved drugs will emerge in the next decade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.